Daniel Peter Petrylak MD

Oncology•New Haven, CT

Genitourinary Oncology, Hematologic Oncology

Yale University Cancer Center

Join to View Full Profile

35 Park Street Np4New Haven, CT 06510
Phone+1 203-200-4822
Fax+1 203-785-4043

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1985 - 1988
Case Western Reserve University School of MedicineClass of 1985

Certifications & Licensure

CT State Medical License 2012 - 2026
NY State Medical License 1985 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
America's Top Doctors Castle Connolly, 2006-2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
New York Magazine: Top Doctors Castle Connolly, 2005-2009, 2011-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer Start of enrollment: 1996 Jan 01
Completed
Phase 3
Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 1998 Feb 01
Unknown status
Phase 1, Phase 2
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer Start of enrollment: 1998 Aug 01
Unknown status
Phase 1
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 1999 Oct 01
Completed
Phase 3
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Start of enrollment: 2001 Feb 01
Completed
Phase 2
S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium Start of enrollment: 2004 Jun 01
Terminated
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
Completed
Phase 1
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Completed
Phase 3
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer Start of enrollment: 2018 Nov 27
Terminated
Phase 2
International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21
RECRUITING
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Off-pore nucleoporin sPOM121 transcriptionally propels β-Catenin driven tumor progression and immune escape in prostate cancer.
Perumalraja Kirthika, Vijayakumar Jawalagatti, Peiyao Li, Michael Xu, Marc Carceles-Cordon
Cancer Discovery. 2025-07-28
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-onl...
Joaquim Bellmunt, Thomas Powles, Se Hoon Park, Eric Voog, Begona P Valderrama
European Urology. 2025-06-03
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-repo...
Shilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, Jens Bedke, Begoña P Valderrama
The Lancet. Oncology. 2025-06-01

Journal Articles

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Jonathan E Rosenberg, Daniel P Petrylak, The New England Journal of Medicine
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Cora N Sternberg, Jeanny B Aragon-Ching, Daniel P Petrylak, Petros Grivas, The New England Journal of Medicine

Lectures

EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
2019 ASCO Annual Meeting - 6/1/2019
6th Annual Interdisciplinary Prostate Cancer Congress®
Physicians' Education Resource, LLC , Physicians' Education Resource, LLC, New York, New York - 3/16/2013

Press Mentions

Pursuing Bladder Cancer Treatments, Reducing Side EffectsMay 20th, 2025
How Did Biden’s Doctors Miss His Condition?May 19th, 2025
Treatment Device Posts “Highest Complete Response Rate Reported to Date” in Bladder Cancer TrialMay 4th, 2025
Join now to see all